Urigen Pharmaceuticals Initiates URG101-104 Phase II Trial

Urigen Pharmaceuticals has initiated a double-blind, placebo controlled, crossover study to investigate URG-101 as a treatment for acute symptoms of painful bladder syndrome/interstitial cystitis (PBS/IC).
 
According to Urigen, the URG101-104 study will compare the efficacy of URG101 (intravesical lidocaine-heparin formulation) and placebo in reducing acute symptoms of PBS/IC.

The study will enroll patients at several U.S. clinical sites, with the first patient having been enrolled and dosed, the company added.